EffRx Pharmaceuticals has announced that US Food and Drug Administration (FDA) has approved Binosto (alendronate sodium) Effervescent Tablets, previously known as EX101.

The tablets are used for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis.

EffRx anticipates that Binosto will be commercially available in the United States in the third quarter of 2012.

Christer Rosén, chairman and CEO of EffRx, said: “Binosto is a breakthrough innovation for the treatment of osteoporosis, offering those patients that have difficulty with tablets the proven fracture risk reduction of alendronate in a pleasant tasting and easy to swallow buffered solution.”

Osteoporosis affects more than 200 million people in the 7 major markets and the global market is estimated to be $10 billion and growing, especially in the emerging markets.

Binosto is an innovative treatment option that can assure physicians that they are providing a proven efficacious therapy for those patients who have difficulty with tablets.

A Harris Interactive Poll concluded that up to 40 per cent of American adults have difficulties with swallowing tablets. – TradeArabia News Service